C

    CDTX (CDTX)

    Official site

    BIOTECHNOLOGY

    $221.38
    +0.00 (+0.00%)

    Last updated: Jan 07, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(20/37)
    Avg Surprise
    -26.68%

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-1.64
    Range$-1.64 - $-1.64
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$-1.39+15.2%
    7d ago$-1.74-6.1%
    Current$-1.64
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-1.64---
    Sep 25
    		$-3.10$-2.77-11.91%Miss-26.5%
    Jun 25
    		$-1.65$-3.04+45.72%Beat+91.7%
    Mar 25
    		$-1.66N/A+52.20%Beat+27.2%
    Dec 24
    		$-5.38$-3.67-46.49%Miss-13350.0%
    Sep 24
    		$-2.45$-4.25+42.35%Beat-2622.2%
    Jun 24
    		$-19.99$-3.22-520.81%Miss-14178.6%
    Mar 24
    		$-2.28$-0.20-1040.00%Miss-7700.0%
    Dec 23
    		$-0.04N/A+60.00%Beat+78.9%
    Sep 23
    		$-0.09$-0.16+43.75%Beat-152.9%
    Jun 23
    		$-0.14$-0.13-7.69%Miss+26.3%
    Mar 23
    		$0.03$-0.04+175.00%Beat+111.1%
    Dec 22
    		$-0.19$-0.17-11.76%Miss+26.9%
    Sep 22
    		$0.17$0.18-5.56%Miss+145.9%
    Jun 22
    		$-0.19$-0.28+32.14%Beat-205.6%
    Mar 22
    		$-0.27$-0.29+6.90%Beat+30.8%
    Dec 21
    		$-0.26$-0.34+23.53%Beat+46.9%
    Sep 21
    		$-0.37$-0.36-2.78%Miss+9.8%
    Jun 21
    		$0.18$-0.08+325.00%Beat+140.0%
    Mar 21
    		$-0.39$-0.26-50.00%Miss+15.2%
    Dec 20
    		$-0.49$-0.24-104.17%Miss-16.7%
    Sep 20
    		$-0.41$-0.38-7.89%Miss-612.5%
    Jun 20
    		$-0.45$-0.28-60.71%Miss+8.2%
    Mar 20
    		$-0.46$-0.34-35.29%Miss+23.3%
    Dec 19
    		$-0.42$-0.43+2.33%Beat+4.5%
    Sep 19
    		$0.08N/A+130.77%Beat+116.3%
    Jun 19
    		$-0.49$-0.57+14.04%Beat+56.6%
    Mar 19
    		$-0.60$-0.60+0.00%Beat+25.0%
    Dec 18
    		$-0.44$-0.59+25.42%Beat+36.2%
    Sep 18
    		$-0.49$-0.60+18.33%Beat+32.9%
    Jun 18
    		$-1.13$-0.66-71.21%Miss-14.1%
    Mar 18
    		$-0.80$-0.64-25.00%Miss+0.0%
    Dec 17
    		$-0.69$-0.76+9.21%Beat+21.6%
    Sep 17
    		$-0.73$-0.94+22.34%Beat+17.0%
    Jun 17
    		$-0.99$-0.88-12.50%Miss-
    Mar 17
    		$-0.80$-0.88+9.09%Beat-
    Dec 16
    		$-0.88$-0.79-11.39%Miss-
    Sep 16
    		$-0.88$-0.88+0.00%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$220.97
    SMA 20$220.65
    SMA 50$187.66
    SMA 200$84.67
    EMA 10$220.93
    EMA 20$217.54
    EMA 50$190.30
    EMA 200$108.45

    MACD

    Line: 7.50Signal: 10.27Hist: -2.77

    ADX

    ADX: 73.4+DI: 53.8-DI: 8.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$218.87

    Bollinger Bands

    Upper Band$221.60
    Lower Band$219.70
    %B Position86%(Upper)
    Band Width0.89

    RSI (14-Day)

    Overbought
    84.2

    Momentum Oscillators

    Stoch %K96.2
    Stoch %D94.7
    Williams %R-2.6
    ROC (10d)0.2%
    Momentum0.53
    CCI (20d)141.8
    MFI (14d)73.6

    Volatility Measures

    ATR (14d)$1.50(0.7%)
    StdDev (20d)0.47
    Hist Vol2.3%(Low)

    Volume Flow

    VWAP$221.38
    OBV70.6M
    AD Line22.4M
    CMF (20d)0.234

    Volume Metrics

    Avg Vol (20d)962.9K
    Vol RatioN/A
    VWMA (20d)$220.66

    Pivot Points

    R3$221.60
    R2$221.51
    R1$221.44
    Pivot Point$221.35
    S1$221.28
    S2$221.19
    S3$221.12

    Advanced Oscillators

    TSI69.94
    Ultimate Osc63.9
    KST277.47

    Financial Data

    QuarterSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total Revenue$0$0$0$-7,490,000$0$302,000$973,000$-17,131,000$9.22M$5.09M$26.11M$10.38M
    Cost of Revenue$0$0$0$83.26M$0$0$0$1.14M$0$0$0$29,000
    Gross Profit$0$0$0$-7,490,000$0$302,000$973,000$-17,131,000$9.22M$5.09M$26.11M$10.38M
    Operating Expenses$88.63M$27.38M$25.27M$44.54M$17.39M$96.29M$9.52M$1.49M$13.69M$11.84M$23.33M$27.43M
    R&D$80.53M$24.82M$24.60M$41.20M$12.43M$91.54M$5.92M$-1,149,000$10.39M$8.66M$18.87M$21.94M
    SG&A$8.10M$6.50M$6.18M$3.34M$4.96M$4.75M$3.60M$2.64M$3.30M$3.18M$4.46M$5.49M
    Operating Income$-88,628,000$-27,384,000$-25,269,000$-52,033,000$-17,394,000$-95,984,000$-8,542,000$-18,625,000$-4,468,000$-6,748,000$2.78M$-17,052,000
    Interest Income$5.39M$1.67M$1.90M$1.81M$1.86M$1.77M$365,000$527,000$613,000$623,000$232,000$162,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-83,233,000$-25,718,000$-23,480,000$-50,220,000$-15,535,000$-94,210,000$-8,177,000$-18,098,000$-3,855,000$-6,125,000$3.01M$-16,890,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-32,000$40,000$0$0
    Net Income$-83,233,000$-25,718,000$-23,480,000$-52,307,000$-15,985,000$-91,209,000$-10,326,000$-3,213,000$-9,107,000$-13,624,000$3.01M$-17,162,000
    EBITDA$-88,766,000$-27,357,000$-25,330,000$-51,974,000$-17,333,000$-95,759,000$-8,470,000$-18,562,000$-4,433,000$-7,158,000$3.29M$-18,795,000
    EBIT$-88,628,000$-27,384,000$-25,379,000$-52,033,000$-17,394,000$-95,984,000$-8,542,000$-18,625,000$-4,468,000$-6,748,000$2.78M$-17,052,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CDTX

    News

    Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

    Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.

    CNBC•8/4/26•
    Neutral

    If You Invested $1,000 in Cidara Theraptcs (CDTX)

    This article analyzes the historical performance of Cidara Therapeutics (CDTX) stock, showing how a $1,000 investment would have fared over 1, 5, and 10 years. It highlights that the company was acquired by Merck in November 2025, ceasing public trading and becoming a wholly-owned subsidiary. The core of Cidara's value centered on its drug-Fc conjugate (DFC) therapeutic platform and its lead candidate, CD388, developed for influenza prevention.

    Stock Titan•7/4/26•
    Neutral

    Cidara Therapeutics Inc (CDTX) Shareholder Structure: Major Shareholders & Institutional Holdings

    This article provides an overview of Cidara Therapeutics Inc (CDTX) shareholder structure, detailing major individual shareholders, the types of institutional holders, and a historical view of institutional shareholding over recent quarters. Key data includes top shareholders like RA Capital Management and Bain Capital, the dominant presence of hedge funds and investment advisors, and quarterly changes in institutional shares held. The article also lists various ETFs with holdings in CDTX.

    TradingKey•6/18/26•
    Neutral

    Cidara Therapeutics (CDTX) 24th Annual Needham Virtual Healthcare Conference summary

    Cidara Therapeutics (CDTX) presented at the 24th Annual Needham Virtual Healthcare Conference, discussing its Cloudbreak immunotherapy platform and the novel antiviral CD388 for influenza. CD388, reacquired in April 2024, is a long-acting antiviral currently in a 5,000-subject Phase II-B study, with promising Phase II-A results. The company anticipates launching Phase III in spring 2026 after ongoing regulatory discussions and capital securing, targeting high-risk populations with CD388 as a single-dose seasonal prophylactic.

    Quartr•6/18/26•
    Somewhat-Bullish

    Cidara Therapeutics Inc (CDTX) Institutional Confidence

    This article provides an analysis of institutional confidence in Cidara Therapeutics Inc (CDTX), showing a breakdown of major institutional shareholders and their recent activity. Key shareholders like The Vanguard Group, Inc., BlackRock Institutional Trust Company, N.A., and Paradigm BioCapital Advisors LP are listed, with some showing a -100.00% change in shares held, indicating a significant decrease in their positions. The data was last updated on January 6, 2026.

    TradingKey•6/17/26•
    Neutral

    Frequently Asked Questions About CDTX

    Does CDTX pay dividends?
    CDTX (CDTX) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In